Jason A. Campagna
Chief Tech/Sci/R&D Officer at Q32 Bio, Inc.
Net worth: - $ as of 29/04/2024
Profile
Jason A.
Campagna is currently the Chief Medical Officer at Q32 Bio, Inc. (Massachusetts) and Q32 Bio, Inc. He previously held positions as Director at Annovation BioPharma, Inc., Managing Director at Profibrix BV, Independent Director at Plantable Health, Inc., Senior VP-Surgery & Perioperative Care at The Medicines Co., and Chief Medical Officer & Senior Vice President at Intercept Pharmaceuticals, Inc. Dr. Campagna has an educational background that includes undergraduate, graduate, and two doctorate degrees from the University of Miami.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
-.--% | 24/03/2024 | 0 ( -.--% ) | - $ | 29/04/2024 |
Jason A. Campagna active positions
| Companies | Position | Start |
|---|---|---|
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
Former positions of Jason A. Campagna
| Companies | Position | End |
|---|---|---|
| PLANTABLE HEALTH INC. | Director/Board Member | 30/03/2023 |
| INTERCEPT PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 04/03/2021 |
| THE MEDICINES COMPANY | Corporate Officer/Principal | 31/07/2016 |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Chief Executive Officer | - |
Annovation BioPharma, Inc.
 Annovation BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ. | Director/Board Member | - |
Training of Jason A. Campagna
| University of Miami | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| PLANTABLE HEALTH INC. | Retail Trade |
| Private companies | 4 |
|---|---|
Annovation BioPharma, Inc.
Annovation BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ. | Health Technology |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Health Technology |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Jason A. Campagna
